The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress

British Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2004, Pages 545-551

  Wenzel, René R ^a,c   Mitchell, Anna ^b   Siffert, Winfried ^b   Bührmann, Sandra ^b   Philipp, Thomas ^b   Schäfers, Rafael F ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Clinic of Internal Medicine   (Austria)

Author keywords

Mental stress; Moxonidine; Physical exercise; Sympathetic activity

Indexed keywords

ADRENALIN; IMIDAZOLINE I1 RECEPTOR; MOXONIDINE; NORADRENALIN; PLACEBO; ADRENERGIC RECEPTOR BLOCKING AGENT; IMIDAZOLE DERIVATIVE; IMIDAZOLONE;

ADRENALIN BLOOD LEVEL; ADULT; AGONIST; ARTICLE; BICYCLE ERGOMETRY; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; EXERCISE TEST; FEMALE; GENETIC ANALYSIS; GENOTYPE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL STRESS; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; PARAMETER; PHYSICAL STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; SYMPATHETIC TONE; DRUG POTENTIATION; EXERCISE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE; EXERCISE TEST; FEMALE; HEART RATE; HUMANS; IMIDAZOLES; MALE; STRESS, PSYCHOLOGICAL; SYMPATHOLYTICS;

EID: 2342511497     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2003.02058.x     Document Type: Article

References (41)

1. Wenzel RR, Bruck H, Noll C, Schäfers RF, Daul AE, Philipp T. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol 2000; 35: 43-52.
2. Converse RL, Jacobsen TN, Jost CM, Toto RD, Grayburn PA, Obregon TM, Fouad-Tarazi F, Victor RG. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 1992; 90: 1657-65.
3. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11(Suppl 1):S19-S27.
4. Grassi G, Turri C, Seravalle G, Bertinieri G, Pierini A, Manda G. Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure. Hypertension 2001; 38: 286-91.
5. 1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension 1998; 32: 1022-7.
6. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E. Effects of low dose sympathetic inhibition on glomerulosderosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-78.
7. Colucci WS. The effects of norepinephrine on myocardial biology, implications for the therapy of heart failure. Clin Cardiol 1998; 21: 120-4.
8. Philipp T, Distler A, Cordes U. Sympathetic nervous system and blood pressure control in essential hypertension. Lancet 1978; ii: 959-63.
9. Noll G, Wenzel RR, de Marchi S, Shaw S, Luscher TF. Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation 1997; 95: 2286-92.
10. Wenzel RR, Allegranza G, Binggeli C, Shaw S, Weidmann P, Luscher TF, Noll G. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol 1997; 29: 1607-14.
11. Eliasson K, Kahan T, Hylander B, Hjemdahl P. Responses to mental stress and physical provocations before and during long term treatment of hypertensive patients with β-adrenoceptor blockers or hydrochlorothiazide. Br J Clin Pharmacol 1987; 24: 1-14.
12. Falkner B, Onesti G, Lowenthal DT, Affrime MB. The use of clonidine monotherapy in adolescent hypertension. Chest 1983; 83: 425-7.
13. Heidbreder E, Schafferhans K, Kirsten R, Heidland A. Effect of diuretics and calcium antagonists on circulatory parameters and plasma catecholamines during mental stress. Eur J Clin Pharmacol 1983; 25: 19-22.
14. Creager MA, Faxon DP, Weiner DA, Ryan TJ. Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril. Br Heart J 1985; 53: 431-5.
15. 3 subunit variant with hypertension. Nat Genet 1998; 18: 45-8.
16. 3 subunit C825T variant and ambulatory blood pressure in essential hypertension. Hypertension 1999; 33: 1049-51.
17. Benjafield AV, Jeyasingam CL, Nyholt DR, Griffiths LR, Morris BJ. G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension 1998; 32: 1094-7.
18. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta (3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37: 739-43.
19. Fagius J, Karhuvaara S. Sympathetic activity and blood pressure increases with bladder distension in humans. Hypertension 1989; 14: 511-7.
20. Hjemdahl P. Catecholamine measurements by high-performance liquid chromatography. Am J Physiol 1984; 247: E13-E20.
21. Michel MC, Brodde OE, Insel PA. Peripheral adrenergic receptors in hypertension. Hypertension 1990; 16: 107-20.
22. Davis SN, Galassetti P, Wasserman DH, Tate D. Effects of gender on neuroendocrine and metabolic counterregulatory responses to exercise in normal man. J Clin Endocrinol Metab 2000; 85: 224-30.
23. Cohn JN. The sympathetic nervous system in heart failure. J Cardiovasc Pharmacol 1989; 14: S57-S61.
24. Hsueh WA, Buchanan TA. Obesity and hypertension. Endocrinol Metab Clin North Am 1994; 23: 405-27.
25. Krieger DR, Landsberg L. Mechanisms in obesity-related hypertension: role of insulin and catecholamines. Am J Hypertens 1988; 1: 84-90.
26. Kuppers HE, Jager BA, Luszick JH, Grave MA, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997; 15: 93-7.
27. Mitrovic V, Patyna W, Huting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5: 967-72.
28. Trenk D, Wagner F, Jahnchen E, Planitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol 1987; 27: 988-93.
29. Kirch W, Hutt HJ, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J Clin Pharmacol 1990; 30: 1088-95.
30. Wenzel RR, Wambach C, Schäfers RF, Daul AE, Michel MC, Siffert W, Philipp T. Doxazosin, but not losartan or enalapril, increases exercise-induced sympathetic activation. Kidney Blood Press Res 1998; 21: 336-398.
31. Lasagna L. Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2000; 283: 2013-4.
32. Fujiwara S, Arita M, Ueno Y, Shiotani M, Nakatsu C, Nakamura Y, Hano T, Nishio I, Masuyama Y. [Effects of calcium antagonist, angiotensin-converting enzyme inhibitors and beta-blocker on hemodynamic and sympathetic nerve responses to exercise in essential hypertension]. J Cardiol 1991; 21: 115-24.
33. Grassi G, Seravalle G, Turri C, Bolla G, Mancia G. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41: 558-62.
34. Sundlof G, Wallin BG, Stromgren E, Nerhed C. Acute effects of metoprolol on muscle sympathetic activity in hypertensive humans. Hypertension 1983; 5: 749-56.
35. Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension 1984; 6: 557-62.
36. Kushwaha SS, Banner NR, Patel N, Cox A, Patton H, Yacoub MH. Effect of beta blockade on the neurohumoral and cardiopulmonary response to dynamic exercise in cardiac transplant recipients. Br Heart J 1994; 71: 431-6.
37. Franz IW, Lohmann FW, Koch G. Oxygen uptake and plasma catecholamines during submaximal and maximal exercise after long-term beta-receptor blockade. Int J Sports Med 1985; 6: 202-6.
38. Schnabel A, Kindermann W, Salas-Fraire O, Cassens J, Steinkraus V. Effect of beta-adrenergic blockade on supramaximal exercise capacity. Int J Sports Med 1983; 4: 278-81.
39. Schäfers RF, Löw-Kröger A, Philipp T. Wirksamkeit und Verträglichkeit des neuen zentralwirksamen Antihypertensivums Moxonidin im Vergleich zu Enalapril. Nieren-Hochdruckkrankheiten 1994; 23: 221-4.
40. Swedberg K, Bergh CH, Dickstein K, McNay J, Steinberg M. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. J Am Coll Cardiol 2000; 35: 398-404.
41. 1- imidazoline agonism: sympathetic mechanisms in hypertension. Hypertension 2000; 35: 1264-9.